India, June 9 -- TG Therapeutics, Inc. (TGTX) announced that 82% of patients in its Phase 1 study of subcutaneous BRIUMVI for myasthenia gravis achieved a clinically meaningful improvement in daily living scores, with a mean gain of more than four points.
The trial enrolled 11 adults with AChR-antibody-positive myasthenia gravis, showing consistent reductions across disease measures over 24 weeks. Median time to improvement was 30 days, and the therapy was generally well tolerated, with safety in line with the established IV formulation.
Building on these results TG has initiated a randomized Phase 2 study designed as a potential registration-directed trial. The approach combines rapid symptom control from FcRn inhibition with longer-term...